Abstract
Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.
Keywords:
HCV; LDV/SOF; hepatitis C infection; ledipasvir; sickle cell disease.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
MeSH terms
-
Adult
-
Anemia, Sickle Cell / complications*
-
Antiviral Agents* / administration & dosage
-
Antiviral Agents* / adverse effects
-
Antiviral Agents* / therapeutic use
-
Benzimidazoles* / administration & dosage
-
Benzimidazoles* / adverse effects
-
Benzimidazoles* / therapeutic use
-
Drug Combinations
-
Female
-
Fluorenes* / administration & dosage
-
Fluorenes* / adverse effects
-
Fluorenes* / therapeutic use
-
Hepatitis C, Chronic* / complications
-
Hepatitis C, Chronic* / drug therapy
-
Humans
-
Male
-
Middle Aged
-
Sofosbuvir* / administration & dosage
-
Sofosbuvir* / adverse effects
-
Sofosbuvir* / therapeutic use
-
Young Adult
Substances
-
Antiviral Agents
-
Benzimidazoles
-
Drug Combinations
-
Fluorenes
-
ledipasvir
-
Sofosbuvir